A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.

[1]  K. Thavorn,et al.  Optimal frequency of scans for patients on cancer therapies: A population kinetics assessment , 2019, Cancer medicine.

[2]  M. Clemons,et al.  Population kinetics of progression free survival (PFS). , 2019, Journal of Clinical Oncology.

[3]  S. Gill,et al.  What is a clinically meaningful survival benefit in refractory metastatic colorectal cancer? , 2019, Current oncology.

[4]  Razelle Kurzrock,et al.  The importance of greater speed in drug development for advanced malignancies , 2018, Cancer medicine.

[5]  P. Royston,et al.  Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards , 2017, British Medical Journal.

[6]  M. Buyse,et al.  Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors , 2017, Drugs.

[7]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[8]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[9]  H. Yasunaga,et al.  Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. , 2016, European journal of cancer.

[10]  M Buyse,et al.  Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Joseph G Ibrahim,et al.  The power prior: theory and applications , 2015, Statistics in medicine.

[12]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[13]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[14]  V. Prasad,et al.  The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. , 2015, JAMA internal medicine.

[15]  M. Buyse,et al.  Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. , 2015, Journal of clinical epidemiology.

[16]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[17]  J. Hecht,et al.  PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Ellis,et al.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Saijo,et al.  Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Motzer,et al.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Kudo,et al.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. LeBlanc,et al.  Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial , 2013, Clinical Cancer Research.

[23]  R. Kurzrock,et al.  Fool’s gold, lost treasures, and the randomized clinical trial , 2013, BMC Cancer.

[24]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Baselga,et al.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Eisenhauer,et al.  Progression-free survival: meaningful or simply measurable? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Val Gebski,et al.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[29]  J. Roth,et al.  Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer. , 2011, Lung cancer.

[30]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[31]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[33]  R. Kurzrock,et al.  Cancer: the road to Amiens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Porta,et al.  Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.